Zhejiang Hisoar Pharmaceutical Hits Day Low at CNY 6.72 Amid Price Pressure

Zhejiang Hisoar Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 5.61% and reaching an intraday low of CNY 6.72. This performance stands in contrast to the China Shanghai Composite, which fell by only 1.24% on the same day. Over the past week, Zhejiang Hisoar has seen a more pronounced downturn, with a 10.86% decrease compared to the composite's 3.38% decline. The company's long-term growth prospects appear challenging, as evidenced by a negative annual growth rate in net sales of 5.79% and a staggering operating profit decline of 179.56% over the last five years. Financial metrics indicate a low return on capital employed (ROCE) of 2.16%, reflecting limited profitability relative to total capital. Additionally, the company reported a net profit of CNY -83.69 million, marking a 162.86% drop, alongside a notably low operating cash flow of CNY 60.01 million. Zhejiang Hisoar's market capitalization stands at CNY 11,906 million, categorizing it as a large-cap entity within the pharmaceuticals and biotechnology sector. The stock's performance raises concerns about its financial health and market position.